Literature DB >> 16702541

Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility.

Jian-Hua Mao1, Elise F Saunier, John P de Koning, Margaret M McKinnon, Mamie Nakijama Higgins, Kathy Nicklas, Hai-Tao Yang, Allan Balmain, Rosemary J Akhurst.   

Abstract

The human TGFB1 gene is polymorphic, and genetic variants are associated with altered cancer risk. However, human genetic association studies have had variable outcomes because TGFbeta1 action is context-dependent. We used the murine skin model of chemical carcinogenesis in genetic linkage analysis of three independent Mus musculus NIH/Ola x (Mus spretus x M. musculus NIH/Ola)F1 backcrosses, to identify a skin tumor susceptibility locus, Skts14, on proximal chromosome 7. Tgfb1 maps at the peak of linkage. The mouse Tgfb1 gene is polymorphic, resulting in cis-regulated differential allelic mRNA expression between M. spretus and M. musculus in F1 mouse skin. This phenomenon is reflected in differential phospho-SMAD2 levels, downstream of TGFbeta signaling, between these two mouse species. In normal F1 mouse skin, the Tgfb1SPR allele is expressed at higher levels than the Tgfb1NIH allele, and this differential is accentuated by phorbol 12-myristate 13-acetate treatment. In benign F1 papillomas, this imbalance is reversed, possibly by selection against expression of a hyperactive Tgfb1SPR allele in TGFbeta growth-responsive tumors. We demonstrate that skin tumor susceptibility is altered by Tgfb1 gene dosage, but that manifestation of Tgfb1-linked skin tumor susceptibility in M. musculus NIH/Ola x (M. spretus x M. musculus NIH/Ola)F1 backcross mice depends on interactions with another unlinked tumor modifying locus, Skts15, that overlaps Tgfbm3 on chromosome 12. These findings illustrate the power of complex genetic interactions in determining disease outcome and have major implications to the assessment of disease risk in individuals harboring variant TGFB1 alleles.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702541      PMCID: PMC1472440          DOI: 10.1073/pnas.0602581103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

Review 1.  TGF-beta signaling in cancer--a double-edged sword.

Authors:  R J Akhurst; R Derynck
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

2.  TbetaR-I(6A) is a candidate tumor susceptibility allele.

Authors:  B Pasche; P Kolachana; K Nafa; J Satagopan; Y G Chen; R S Lo; D Brener; D Yang; L Kirstein; C Oddoux; H Ostrer; P Vineis; L Varesco; S Jhanwar; L Luzzatto; J Massagué; K Offit
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

3.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.

Authors:  D R Welch; A Fabra; M Nakajima
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

4.  Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells.

Authors:  Tatsuru Ota; Makiko Fujii; Takashi Sugizaki; Masami Ishii; Keiji Miyazawa; Hiroyuki Aburatani; Kohei Miyazono
Journal:  J Cell Physiol       Date:  2002-12       Impact factor: 6.384

5.  A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.

Authors:  G Torre-Amione; R D Beauchamp; H Koeppen; B H Park; H Schreiber; H L Moses; D A Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

6.  Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta.

Authors:  M H Sieweke; N L Thompson; M B Sporn; M J Bissell
Journal:  Science       Date:  1990-06-29       Impact factor: 47.728

7.  Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins.

Authors:  A Lasorella; M Noseda; M Beyna; Y Yokota; A Iavarone
Journal:  Nature       Date:  2000-10-05       Impact factor: 49.962

8.  Genetic control of the circulating concentration of transforming growth factor type beta1.

Authors:  D J Grainger; K Heathcote; M Chiano; H Snieder; P R Kemp; J C Metcalfe; N D Carter; T D Spector
Journal:  Hum Mol Genet       Date:  1999-01       Impact factor: 6.150

9.  Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.

Authors:  Pamela L Paris; Armann Andaya; Jane Fridlyand; Ajay N Jain; Vivian Weinberg; David Kowbel; John H Brebner; Jeff Simko; J E Vivienne Watson; Stas Volik; Donna G Albertson; Daniel Pinkel; Janneke C Alers; Theodorus H van der Kwast; Kees J Vissers; Fritz H Schroder; Mark F Wildhagen; Phillip G Febbo; Arul M Chinnaiyan; Kenneth J Pienta; Peter R Carroll; Mark A Rubin; Colin Collins; Herman van Dekken
Journal:  Hum Mol Genet       Date:  2004-05-11       Impact factor: 6.150

10.  Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells.

Authors:  E Van Obberghen-Schilling; N S Roche; K C Flanders; M B Sporn; A B Roberts
Journal:  J Biol Chem       Date:  1988-06-05       Impact factor: 5.157

View more
  20 in total

1.  Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.

Authors:  Erin C Connolly; Elise F Saunier; David Quigley; Minh Thu Luu; Angela De Sapio; Byron Hann; Jonathan M Yingling; Rosemary J Akhurst
Journal:  Cancer Res       Date:  2011-01-31       Impact factor: 12.701

2.  Mapping of new skin tumor susceptibility loci by a phenotype-driven congenic approach.

Authors:  Kyoko Fujiwara; Yoshinori Inagaki; Masayoshi Soma; Toshinori Ozaki; Hiroki Nagase
Journal:  Oncol Lett       Date:  2018-09-24       Impact factor: 2.967

Review 3.  Systems genetics analysis of cancer susceptibility: from mouse models to humans.

Authors:  David Quigley; Allan Balmain
Journal:  Nat Rev Genet       Date:  2009-07-28       Impact factor: 53.242

Review 4.  The complexities of TGF-β action during mammary and squamous cell carcinogenesis.

Authors:  Erin C Connolly; Rosemary J Akhurst
Journal:  Curr Pharm Biotechnol       Date:  2011-12       Impact factor: 2.837

5.  Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.

Authors:  Christopher S Hackett; David A Quigley; Robyn A Wong; Justin Chen; Christine Cheng; Young K Song; Jun S Wei; Ludmila Pawlikowska; Yun Bao; David D Goldenberg; Kim Nguyen; W Clay Gustafson; Sundari K Rallapalli; Yoon-Jae Cho; James M Cook; Serguei Kozlov; Jian-Hua Mao; Terry Van Dyke; Pui-Yan Kwok; Javed Khan; Allan Balmain; QiWen Fan; William A Weiss
Journal:  Cell Rep       Date:  2014-10-23       Impact factor: 9.423

6.  New outbred colony derived from Mus musculus castaneus to identify skin tumor susceptibility loci.

Authors:  Kyoko Fujiwara; Benjamin Wie; Rosemary Elliott; Hiroki Nagase
Journal:  Mol Carcinog       Date:  2010-07       Impact factor: 4.784

7.  Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus.

Authors:  Julia Freimuth; Frederic F Clermont; Xiaozhu Huang; Angela DeSapio; Taku A Tokuyasu; Dean Sheppard; Rosemary J Akhurst
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-11       Impact factor: 11.205

Review 8.  A role for TGFbeta signaling in the pathogenesis of psoriasis.

Authors:  Gangwen Han; Cortny A Williams; Kelli Salter; Pamela J Garl; Allen G Li; Xiao-Jing Wang
Journal:  J Invest Dermatol       Date:  2009-08-27       Impact factor: 8.551

Review 9.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

10.  Sequence divergence of Mus spretus and Mus musculus across a skin cancer susceptibility locus.

Authors:  Kimberly L Mahler; Jessica L Fleming; Amy M Dworkin; Nicholas Gladman; Hee-Yeon Cho; Jian-Hua Mao; Allan Balmain; Amanda Ewart Toland
Journal:  BMC Genomics       Date:  2008-12-23       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.